

REMARKS

The application has been amended to insert the required reference to the parent applications, for which benefit is claimed, of this new divisional application. The additional amendments to the specification add sequence identifiers to the Brief Description of the Figures for Figures 2A1 and 3A, which include sequences. This addition does not add new matter. Similarly, the Amendment to the specification to add a substitute Sequence Listing does not add new matter because the substitute sequence listing recites only sequences found in the specification as filed.

The amendments to the drawings were made to correct the definition of the letters, the margins, and the labeling of the views in accordance with the Draftperson's patent drawing review entered in the parent application.

Claims 1-5 and 13-24 have been canceled, claim 6 has been amended, and new claims 25-28 have been added, leaving claims 6-12 and 25-28 pending and under examination. These claims were identified by the Office during the prosecution of the parent application as Group III, drawn to a method of preventing infection using a molecule that inhibits growth or infection of *Helicobacter*. (Office Action dated March 18, 2002, U.S. Application No. 09/742,361).

Support for amended claim 6 and new claims 25-28 can be found throughout the specification, and no new matter enters by amendment. Specific support can be found as follows:

<u>Claim</u>	<u>Support</u>
6	Original claims 1, 5, and 6.
25	Original claim 13
26	Page 7, II. 8-10.
27	Page 7, II. 10-18

Claim
28

Support
Page 7, ll. 10-18.

Please grant any extensions of time required to enter this paper and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: November 25, 2003

By: 
Kenneth J. Meyers
Reg. No. 25,146
Phone: (202)408-4033
Fax: (202)408-4400
Email: ken.meyers@finnegan.com

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com